Digital transformation in diagnostics: Six technologies impacting the future of the lab

• From the lab bench to the patient’s home, six emerging technologies are accelerating  digital transformation in the lab: predictive next-generation sequencing (NGS), wearables, mass spectrometry, artificial intelligence (AI) imaging, liquid biopsies, Point of Care Testing (POCT)
• Digitalization trends can help bridge staffing gaps and meet rising demand by streamlining workflows and expanding equitable access to care
• To stay competitive and relevant, start now: prioritize use cases, modernize your data infrastructure, and upskill your teams

Digital transformation in diagnostics is reshaping laboratory medicine amid rising demands for testing, staffing gaps, budget pressures, and more personalized care. From central labs to Point of Care settings, organizations must modernize or risk falling behind.

Here, we unpack six technologies driving lab digital transformation: AI imaging, NGS, liquid biopsy, mass spectrometry, wearables, and POCT. You’ll get practical steps to begin digital transformation in the laboratory to support a decrease in manual intervention, fewer errors, and faster answers for clinicians and patients.

The impact of the Fourth Industrial Revolution (also known as 4IR or Industry 4.0) is already evident in diagnostic testing. Labs are deploying an expanding mix of digital solutions to streamline processes, shorten turnaround times, and improve the reliability of results. Meanwhile, the diagnostic toolbox is moving beyond the central lab—into clinics, pharmacies, patients’ homes, and even onto patients themselves.¹

Together, these digital and technological trends are redefining the diagnostic landscape, making it essential for lab leaders to prioritize investments, modernize data infrastructure, and upskill teams to fully leverage digital transformation. By taking these steps, labs can improve efficiency, enhance quality, and expand access to care while staying competitive in an evolving industry.

When it comes to digital transformation in the lab, six key innovations are leading the way: Predictive genetic testing and next-generation sequencing (NGS), wearable biosensors, mass spectrometry, artificial intelligence (AI)-assisted medical imaging, liquid biopsies, and point-of-care testing (POCT).

Predictive genetic testing using NGS analyzes blood, saliva, or tissue to estimate an individual’s future disease risk. By flagging pathogenic variants before symptoms appear, predictive genetic testing enables targeted prevention. This can include earlier lifestyle or pharmacologic interventions, intensified screening, prophylactic care, and more personalized treatment plans.²

Clinical use is expanding from rare Mendelian disorders to common conditions through multi-gene panels and polygenic risk scores. Faster NGS turnaround times and lower costs now allow many labs to return results within days and routinely cover hundreds of genes.^3,4

Wearable devices, from watches, clothing, bandages, glasses, contact lenses, and rings to implantable or ingestible sensors, capture information such as heart rate, blood pressure, skin temperature, respiratory rate, and motion. 

These continuous data streams feed digital diagnostics workflows, enabling remote monitoring and triggering alerts when values drift toward risk or deviate from normal ranges.⁵

In chronic disease management, longitudinal signals from wearables can be combined with lab biomarkers to guide earlier therapy adjustments. When anomaly-detection algorithms spot early shifts, they can prompt a confirmatory lab test or a telehealth check-in, enabling timely intervention and closing the loop between patient-generated data and the lab’s digital workflow.⁶

Mass spectrometers have been widely used since the mid-20th century to measure molecules by mass-to-charge ratio. In diagnostics, targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) delivers greater analytical specificity and sensitivity than antibody-based immunoassays, avoiding issues such as cross-reactivity, heterophile interference, and narrow dynamic ranges.^7,8

A single LC-MS/MS run can quantify multiple analytes and metabolites at trace levels, resolve isoforms, and confirm positives. These capabilities underpin core clinical workflows, including steroid panels, therapeutic drug monitoring, toxicology, and newborn screening.⁸

Building on these LC-MS/MS strengths in routine testing, the current wave of lab digital transformation is tightening the entire pipeline: automation of sample preparation, software-guided acquisition and processing, curated spectral libraries, and LIS integration reduce hands-on time and variability — making multi-analyte panels more scalable in everyday practice.⁹

AI systems are already helping clinicians interpret medical images faster and more consistently across radiology and pathology, supporting triage, quality control, and decision-making. 

Applications range from mammography triage and stroke/large vessel occlusion alerts to slide-level tumor detection, region segmentation, and automated biomarker scoring (e.g., Ki-67, HER2) on digitized tissue.¹⁰

In breast screening, the 2023 Mammography Screening with AI (MASAI) randomized trial showed a 44% reduction in reading workload while maintaining cancer detection and improving positive predictive value (28.3% vs. 24.8%).¹¹ In prostate pathology, AI-assisted workflows enhanced pathologists' efficiency on biopsy reads, supporting adoption into routine practice.¹²

A liquid biopsy involves testing blood or urine samples to identify indicators of cancer, such as circulating tumor cells or tumor DNA. These tests are less invasive than a tissue biopsy and may expand access to targeted therapies for more patients. 

Building on this, liquid biopsies support precision medicine and earlier detection by surfacing actionable mutations and minimal residual disease from a simple sample^.13 Faster turnaround times, lower procedural costs, and fewer complications enhance efficiency, affordability, and patient comfort. 

As labs continue to evolve, liquid biopsy data can feed into digital diagnostics, analytics, and decision-support systems. This integration helps guide therapy selection and longitudinal monitoring, making liquid biopsies a practical pillar of lab digital transformation.¹³

Point of Care testing moves critical assays out of the central lab, giving clinicians rapid access to results where care happens. By eliminating transport and batching, it cuts time-to-result from hours to minutes, speeding triage and treatment decisions. 

In remote and rural settings, portable analyzers and connected readers bring reliable testing to clinics, pharmacies, and mobile units. Results can be synced directly to digital diagnostics platforms and electronic health records for immediate action.¹⁴

Point of Care testing also supports outreach and telehealth workflows by enabling on-the-spot screening, infectious disease detection, and chronic disease monitoring near the patient, extending the laboratory’s reach and impact beyond its walls.

Digital change is already here. To move from intent to impact, use a simple two-track plan—platforms and data and people and practice—anchored by measurable metrics.

1. Platforms and data (technology + infrastructure): Pilot one or two high-value use cases (e.g., turnaround-time or error-rate reduction in 90 days) while building the backbone that makes them stick: LIS/LIMS interoperability, secure cloud storage, governed data models, instrument connectivity, and automation. Ensure data accessibility and sharing so results flow into dashboards that guide action.
2. People and practice (upskilling + change): Deliver role-based training on quality dashboards, AI outputs, and automated workflows; designate super-users to coach peers; and embed SOPs, validation, and change management so improvements are safe, compliant, and repeatable.

Net effect: Streamlined workflows, faster turnaround, fewer handoffs and errors—and more time for patient care.

For lab leaders, the opportunity is clear: Translate today’s constraints—rising demand, tight budgets, workforce gaps—into durable advantages by scaling the platforms and data and people and practice tracks across sites.

Prioritize three strategic moves:

• Scale proven use cases with interoperable data and governance that travel across disciplines
• Institutionalize capability building (super-users, role-based curricula) so teams confidently operate AI, automation, and digital diagnostics
• Hardwire quality and change management into every rollout to sustain gains

Measure what matters so investments convert into tangible outcomes and year-over-year efficiency: Faster, more accurate results, extended community reach, and resilient operations.